UMPIRE

Use of a Multidrug Pill In Reducing cv Events

Coordinatore	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE    more  Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Ms. Nome: Tatjana Cognome: Palalic Email: send email Telefono: +44 20 7594 3866 Fax: +44 20 7594 3868
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	4˙154˙961 €
EC contributo	2˙999˙866 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2009-single-stage
Funding Scheme	CP-FP
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-02-01   -   2013-01-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE  Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Ms. Nome: Tatjana Cognome: Palalic Email: send email Telefono: +44 20 7594 3866 Fax: +44 20 7594 3868	UK (LONDON)	coordinator	969˙149.00
2	ROYAL COLLEGE OF SURGEONS IN IRELAND  Organization address address: Saint Stephen's Green 123 city: DUBLIN postcode: 2 contact info Titolo: Ms. Nome: Barbara Cognome: Gallagher Email: send email Telefono: +353 1 809 2862 Fax: +353 1 809 3809	IE (DUBLIN)	participant	502˙072.00
3	UNIVERSITAIR MEDISCH CENTRUM UTRECHT  Organization address address: HEIDELBERGLAAN 100 city: UTRECHT postcode: 3584 CX contact info Titolo: Dr. Nome: Anne/Marie Cognome: Laeven Email: send email Telefono: -3814 Fax: +31-88-755 5485	NL (UTRECHT)	participant	501˙602.00
4	CENTRE FOR CHRONIC DISEASE CONTROL SOCIETY  Organization address address: VASANT KUNJ TOWER 4 SECTOR C POCKET 9 VASANT KUNJ city: NEW DELHI postcode: 110070 contact info Titolo: Mr. Nome: Alex Cognome: Irudayaraj Email: send email Telefono: +91 11 268 50117 Fax: +91 11 2685 0588	IN (NEW DELHI)	participant	417˙228.44
5	George Institute for Global Health  Organization address address: "Plot No.839C, Road No. 44A, Jubilee Hills" city: Hyderabad postcode: 500033 contact info Titolo: Dr. Nome: A. Sunder Cognome: Rajan Email: send email Telefono: +91 40 2355 8091 Fax: +91 40 2354 1980	IN (Hyderabad)	participant	413˙628.44
6	THE GEORGE INSTITUTE FOR INTERNATIONAL HEALTH LIMITED  Organization address address: "MISSENDEN ROAD, George V Building Royal Prince Alfred hospital Missenden Road Camperdown Level 10" city: SYDNEY postcode: NSW 2050 contact info Titolo: Mr. Nome: Richard Cognome: Fisher Email: send email Telefono: +61 2 8238 2444 Fax: +61 2 9657 0301	AU (SYDNEY)	participant	178˙586.12
7	PUBLIC HEALTH FOUNDATION OF INDIA  Organization address address: "SIRIFORT INSTITUTIONAL AREA, AUGUST KRANTI MARG, PHD HOUSE 4/2, 2ND FLOOR" city: NEW DELHI postcode: 110016 contact info Titolo: Mr. Nome: Palghat Krishnan Cognome: Sriraman Email: send email Telefono: +91 11 46046053 Fax: +91 11 41648513	IN (NEW DELHI)	participant	17˙600.00
8	Dr. Reddy's Laboratories Ltd  Organization address address: Ameerpet 7-1-27 city: Hyderabad postcode: 500016 contact info Titolo: Mr. Nome: Narasimham Cognome: M V Email: send email Telefono: +91 40 66022564 Fax: +91 40 66022595	IN (Hyderabad)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Cardiovascular disease is the focus of this proposal as it is the leading cause of mortality worldwide. People with established vascular disease represent a target for secondary prevention using combination therapy that addresses multiple risk factors. Barriers to effective delivery of proven secondary preventative treatments create important gaps in the uptake. These gaps vary in different countries. Complexity and cost of treatment confer particularly difficult barriers; typically an individual recovering from a stroke or heart attack might be advised to take multiple medications to address cholesterol, blood pressure and platelet function. A combination once daily polypill may address these issues. Such a pill, the Red Heart Pill, has been formulated by Dr Reddy’s Laboratories in India. It is remarkably inexpensive with a projected annual cost in India of about €15. Evidence of safety and efficacy of this low-cost fixed-dose, once-daily polypill derived from a carefully conducted clinical trial will support its use in resource-poor countries and internationally. This project aims to evaluate whether provision of a cardiovascular polypill compared with usual medications improves adherence to therapies and clinical outcomes among high-risk patients. Further aims are to measure prescription of combination therapy, barriers to adherence, quality of life, safety, cardiovascular events, and healthcare resource consumption. The results will be used to develop recommendations for equitable access relevant to both Europe and India. India has been chosen as an ICPC partner as it is the home of a large global generic pharmaceutical company – Dr Reddy’s – and about 1 in 4 heart attacks globally occur in India. Parallel polypill projects running in Australia and New Zealand will afford the opportunity of pooling data to assess effects on cardiovascular outcomes. This synergy will enhance the generalisable impact of the UMPIRE trial.'